Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kyle Kumbier"'
Autor:
Megan E. V. Caram, Kyle Kumbier, Phoebe A. Tsao, Jennifer Burns, Jordan B. Sparks, Kristian D. Stensland, Zachery R. Reichert, Joshi J. Alumkal, Brent K. Hollenbeck, Vahakn Shahinian, Alexander Tsodikov, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Introduction Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease with prognoses varying from months to years at time of castration‐resistant diagnosis. Optimal first‐line therapy for those with different
Externí odkaz:
https://doaj.org/article/e87d252553e64f07b78df5cbebfcca3e
Autor:
Phoebe A. Tsao, Jennifer Burns, Kyle Kumbier, Jordan B. Sparks, Shami Entenman, Lindsey E. Bloor, Amy S. B. Bohnert, Ted A. Skolarus, Megan E. V. Caram
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 16490-16501 (2023)
Abstract Background Abiraterone and enzalutamide are castration‐resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets. Methods We used national Veter
Externí odkaz:
https://doaj.org/article/d95095a5a3ee48ecb1498054bf1924b9
Autor:
Megan E. V. Caram, Kyle Kumbier, Jennifer Burns, Jordan B. Sparks, Phoebe A. Tsao, Kristian D. Stensland, Samuel L. Washington III, Brent K. Hollenbeck, Vahakn Shahinian, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6945-6955 (2023)
Abstract Background Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC). We investigated the differential adoption of abiraterone and enzalutamide
Externí odkaz:
https://doaj.org/article/8e7c0dabb2ab4edb91d46c692eb5454b
Autor:
Amy SB Bohnert, Kyle Kumbier, Mazhgan Rowneki, Ashwin Gupta, Kristina Bajema, Denise M Hynes, Elizabeth Viglianti, Ann M O’Hare, Thomas Osborne, Edward J Boyko, Yinong Young-Xu, Theodore J Iwashyna, Matthew Maciejewski, Richard Schildhouse, Derek Dimcheff, George N Ioannou
Publikováno v:
BMJ. :e074521
Objectives To determine the association between covid-19 vaccination types and doses with adverse outcomes of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during the periods of delta (B.1.617.2) and omicron (B.1.1.529) varia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::415670738b6da39db91752dd97a00c09
https://doi.org/10.1136/bmj-2022-074521
https://doi.org/10.1136/bmj-2022-074521
Publikováno v:
Gastroenterology. 163:308-309.e3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9a46099a32c4648eaee2493ef238cef
https://doi.org/10.1053/j.gastro.2022.03.013
https://doi.org/10.1053/j.gastro.2022.03.013
Autor:
Jennifer Burns, Brent K. Hollenbeck, Jordan Bauman, Phoebe A. Tsao, Jordan B. Sparks, Christina H. Chapman, Kyle Kumbier, Vahakn B. Shahinian, Ted A. Skolarus, Megan E.V. Caram
Publikováno v:
Cancer
BACKGROUND Treatments for metastatic castration-resistant prostate cancer (CRPC) differ in toxicity, administration, and evidence. In this study, clinical and nonclinical factors associated with the first-line treatment for CRPC in a national deliver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208f99abf7a3660858713b9d5f4630e4
https://europepmc.org/articles/PMC8195818/
https://europepmc.org/articles/PMC8195818/
Autor:
Megan Veresh Caram, Kyle Kumbier, Phoebe A. Tsao, Jennifer A. Burns, Jordan Sparks, Jordan Bauman, Kristian Stensland, Brent K. Hollenbeck, Vahakn B. Shahinian, Ted A. Skolarus
Publikováno v:
Journal of Clinical Oncology. 40:67-67
67 Background: Several therapies for men with castration-resistant prostate cancer (CRPC) have become available since 2010 with the hope of prolonging survival for those at the end stages of their disease. Little is known about the survival of men wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0040e8ecc224b50b96a5f3c97b90d802
https://doi.org/10.1200/jco.2022.40.6_suppl.067
https://doi.org/10.1200/jco.2022.40.6_suppl.067
Autor:
Kyle Kumbier, Jordan Sparks, Megan E.V. Caram, Jordan Bauman, Ted A. Skolarus, Vahakn B. Shahinian, Phoebe A. Tsao, Jennifer A. Burns
Publikováno v:
Journal of Clinical Oncology. 39:6582-6582
6582 Background: Skeletal related events (SREs) are a known complication for the 80% of men with metastatic prostate cancer who have bone metastases. Previous studies have demonstrated that bone modifying agents (BMAs) such as zoledronic acid and den
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e8c9678172dac4892a5e052721b3bc
https://doi.org/10.1200/jco.2021.39.15_suppl.6582
https://doi.org/10.1200/jco.2021.39.15_suppl.6582
Autor:
Phoebe A. Tsao, Jennifer A. Burns, Megan E.V. Caram, Ted A. Skolarus, Shami Entenman, Jordan Sparks, Kyle Kumbier, Amy S.B. Bohnert
Publikováno v:
Journal of Clinical Oncology. 39:e18680-e18680
e18680 Background: Abiraterone and enzalutamide are oral therapies widely used to treat men with castration-resistant prostate cancer (CRPC). Recent data have suggested potentially worsened quality of life and depression with use of enzalutamide comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb5c626b834789bd9bb0c134eca9f9a0
https://doi.org/10.1200/jco.2021.39.15_suppl.e18680
https://doi.org/10.1200/jco.2021.39.15_suppl.e18680